In all 3 patients treated in the INCIPIENT trial so far, the tumor tissue from the initial resection in the newly diagnosed setting was EGFR variant III tumor-specific (EGFRvIII) positive, and in 2 of these 3 patients also the tumor tissue resected at progression prior to the CAR-T cell therapy was EGFRvIII positive. Here, EGFR is linked to neoplasm.